EACS2023: 881 Real-world clinical outcomes of HIV-1 virologically suppressed adults on bictegravir/emtricitabine/tenofovir alafenamide who switched to long-acting intramuscular cabotegravir+rilpivirine at 12-, 24-, and 48-weeks K. Nasser , A.-M. Valentin , M. Ramgopal Midway Specialty Care Center, Clinical Research, Fort Pierce, United States General data Abstract category: Antiretroviral therapy – observational studies Abstract body Purpose: CAB+RPV is a long-acting injectable (LAI) that can be used for patients who want to reduce the frequency of antiretroviral (ART) administration. CAB+RPV allows for virologic suppression (VS) with bimonthly administration. The purpose of this study is to compare real-world clinical outcomes with SOLAR study results, to evaluate the efficacy of CAB+RPV in VS adults living with HIV-1 who switched from BIC/FTC/TAF. Method: This retrospective study included patients treated with CAB+RPV who switched from BIC/FTC/TAF in clinical practice from May 2021 to March 2023 at 10 Florida clinics. We collected data on patient characteristics, plasma viral load (pVL), CD4+ count, and clinical and laboratory efficacy data at 12-, 24-, and 48-weeks. Statistical analyses were descriptive. Endpoints assessed include: pVL, CD4+ count, virologic failure (VF), resistance, BMI, serum glucose, creatinine, and estimated eGFR. Results: 79 VS patients on BIC/FTC/TAF were switched to CAB+RPV. The majority were male (61%) and Caucasian (59%). Median age at baseline was 47 years (range 19-91). 6 patients (7.8%) discontinued, 3 discontinuations due to injection site pain, 2 lost to follow-up, and 1 due to fatigue. All discontinuations were within 3 months, 51 (64.5%) had complete data through 48-weeks. At baseline, 100% had pVL <200 (90% with pVL <50), 100% had CD4+ >200 (76.5% with CD4+ >500), median duration on BIC/FTC/TAF was 89.7 weeks. At 48-weeks, 100% remained VS with pVL <200 (90.2% with pVL <50), 100% had CD4+ >200 (76.5% with CD4+ >500). No drug resistance or VF observed. Viral blips among those VS were observed in 4 (7.8%), but achieved pVL <50 by 48-weeks. 3 with pVL <50 experienced pVL >50 but <200 by 48-weeks. Conclusions: Real-world outcomes show that patients switching from BIC/FTC/TAF to CAB+RPV remain VS. CAB+RPV is non-inferior, in line with SOLAR study results. Patients with observed viral blips remained VS at 48 weeks. General conditions 1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after the submission deadline and I am aware that it will be published exactly as submitted.: Yes 2. I confirm that the submission of the abstract constitutes my consent to publication (e.g. conference website, programmes, other promotions, etc.). : Yes 3. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.: Yes 4. I agree that all data provided may be used (saved, stored, processed, transmitted and deleted) in compliance with the privacy policy to provide the services described.: Yes 1 1 1 1 168 19TH EUROPEAN AIDS CONFERENCE | WARSAW 2023
RkJQdWJsaXNoZXIy Mzc2ODc=